Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab-awwb + Carboplatin + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab-awwb||Mvasi||ABP 215||VEGF Antibody 11||Mvasi (bevacizumab-awwb) is a biosimilar to the anti-VEGF antibody Avastin (bevacizumab), which binds to and inhibits VEGF, resulting in decreased tumor growth and angiogenesis (PMID: 29743182). Mvasi (bevacizumab-awwb) is FDA approved for use in combination with chemotherapy in colorectal cancer, in combination with carboplatin and paclitaxel in non-squamous non-small cell lung cancer, in glioblastoma, in combination with interferon-alfa in renal cell carcinoma, and in combination with paclitaxel and cisplatin or topotecan in cervical cancer (FDA.gov).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-squamous non-small cell carcinoma||not applicable||Bevacizumab-awwb + Carboplatin + Paclitaxel||FDA approved||Actionable||In a Phase III trial that supported FDA approval, Mvasi (bevacizumab-awwb) treatment resulted in an objective response rate (ORR) of 39% (128/328) similar to the ORR of Avastin (bevacizumab), 41.7% (131/314), in non-squamous NSCLC patients receiving Carboplatin and Paclitaxel as first line therapy, and was pharmacokinetically similar to Avastin (bevacizumab) further supporting extrapolation to other indications (J Clin Oncol 34, 15_sup (2016) 9095, J Clin Oncol 35, 15_sup (2017) 9050, FDA.gov; NCT01966003).||detail... detail... detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|